MRD-Driven Oncology Trials: Regulatory, Clinical and Pharmacology Considerations
Examine how sponsors can thoughtfully incorporate MRD across early-phase and registrational development.
Tuesday, May 19, 2026 | 12pm EDT : How AI Can Reduce Inspection Risk and Strengthen QMSR Readiness
In this month’s featured editorial, we take a closer look at the return of biotech IPO activity in 2026, as companies begin to re-enter the public markets after a more cautious funding period. You’ll also find upcoming webinars covering clinical trial optimization and biopharma manufacturing, with practical perspectives on study design and execution alongside process efficiency and scale-up.
We’re also inviting you to weigh in on a timely industry question: as regulators expand their use of AI in review processes, should these tools play a larger role in accelerating drug approvals?
Explore the featured blog, register for upcoming webinars and share your view in this month’s poll.
Vera Kovacevic, PhDEditor-in-ChiefXtalks — The Life Science Community™
Check out this month’s featured article from our life science editorial team.
Track the biotech IPOs shaping 2026, and the therapies and technologies driving their move to the public markets.
Register free for our upcoming webinars, covering a wide range of topics in pharma, biotech, medtech, healthcare and research.
Examine how sponsors can thoughtfully incorporate MRD across early-phase and registrational development.
Discover a practical view of how AI, decentralized trial technologies and modeling and simulation are being used in clinical trials today.
Gain practical insights into aligning non-GMP prototyping with GMP-compliant manufacturing to support regulatory readiness.
Catch up on the latest Xtalks video content as selected by our Editor-in-Chief, Vera Kovacevic, PhD.
Host Dr. Corey Stanton chats with Neal Dunkinson, Sr. Director of Solution Sales at Copyright Clearance Center (CCC), about why copyright and licensing are becoming mission-critical in modern life sciences research, particularly in the era of AI.
More About This EpisodeXtalks spoke with Samuel Hernandez, PhD, SVP Site Head at FUJIFILM Biotechnologies’ Texas facility, about how scaling AAV production to 2,000 L single-use bioreactors can help support a more commercially viable path for gene therapy innovators.
More About This InterviewCast your vote and weigh in on this month’s pressing topic facing our life science community.
Xtalks Insights